Advances in Therapy

, 19:209 | Cite as

Arnica montana gel in osteoarthritis of the knee: An open, multicenter clinical trial

  • Otto Knuesel
  • Michel Weber
  • Andy Suter


This open multicenter trial investigated the safety and efficacy of anArnica montana fresh plant gel, applied twice daily, in 26 men and 53 women with mild to moderate osteoarthritis (OA) of the knee. After 3 and 6 weeks, significant decreases in median total scores on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) were evident in the intention-to-treat and per-protocol populations (both P<.0001). Scores on the pain, stiffness, and function subscales also showed significant reductions at these timepoints. The overall local adverse-event rate of 7.6% included only one allergic reaction. Sixty-nine patients (87%) rated the tolerability of the gel as “good” or “fairly good,” and 76% would use it again. Topical application ofArnica montana gel for 6 weeks was a safe, well-tolerated, and effective treatment of mild to moderate OA of the knee.


arnica clinical trial osteoarthritis WOMAC 


  1. 1.
    Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States.Arthritis Rheum. 1998;43:778–799.CrossRefGoogle Scholar
  2. 2.
    Dequeker J, Dieppe PA. Disorders of bone cartilage and connective tissue. In: Klippel JH, Dieppe PA, eds.Rheumatology. 2nd ed. London: Mosby; 1998:24–25.Google Scholar
  3. 3.
    Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs.N Engl J Med. 1999;340(24):1888–1899.PubMedCrossRefGoogle Scholar
  4. 4.
    Bolten W, et al. Konsequenzen und Kosten der NSA-Gastropathie in Deutschland.Akt Rheurnatol. 1999;24:127–134.CrossRefGoogle Scholar
  5. 5.
    Mayer JG, Czygan F-C.Arnica montana L., oder Bergwohlverleih.Z Phytother. 2000;21:30–36.Google Scholar
  6. 6.
    European Scientific Cooperative on Phytomedicine (ESCOP).Arnica flos. July 1997.Google Scholar
  7. 7.
    Lyss G, Schmidt TJ, Merfort I, Pahl HL. Helenalin, an anti-inflammatory sesquiterpene lactone from Arnica, selectively inhibits transcription factor NF-gkB.Biol Chem. 1997;378:951–961.PubMedCrossRefGoogle Scholar
  8. 8.
    Moog JB. Een medisch experimentel onderzoek naar de werkzamheid van een uitwendige toepassing van Arnica-gelei.Tijdschr Integr Geneesk. 1993;9:105–112.Google Scholar
  9. 9.
    Brock FE.Arnica montana bei Venenleiden.Z Phytother. 1991;12:141–145.Google Scholar
  10. 10.
    Hausen BM. Arnikaallergie.Hausarzt. 1980;31:10–17.Google Scholar
  11. 11.
    Hausen BM. A 6-year experience with compositae mix.Am J Contact Dermat. 1996;7:94–99.PubMedCrossRefGoogle Scholar
  12. 12.
    Bellamy N.WOMAC Osteoarthritis Index. User Guide IV. 2000.Google Scholar
  13. 13.
    Moore RA, Tramér MR, Carroll D, Wiffen PJ, McQuay HJ. Quantitative systemic review of topically applied non-steroidal anti-inflammatory drugs.BMJ. 1998;316:333–338.PubMedGoogle Scholar
  14. 14.
    Heyneman CA. Oral versus topical NSAIDs in rheumatic diseases.Drugs. 2000;60:555–574.PubMedCrossRefGoogle Scholar
  15. 15.
    Reider N, Komericki P, Hausen BM, Fritsch P, Aberer W. The seamy side of natural medicines: contact sensitisation to arnica (Arnica montana L.) and marigold (Calendula officinalis L.).Contact Dermatitis. 2001;45:269–272.PubMedCrossRefGoogle Scholar
  16. 16.
    Committee for Proprietary Medicinal Products.Points to Consider on Clinical Investigation of Medicinal Products Used in the Treatment of Osteoarthritis. London: CPMP; July 23, 1998.Google Scholar
  17. 17.
    Food and Drug Administration.Clinical Development Programs for Drugs, Devices, and Biological Products Intended for the Treatment of Osteoarthritis. Draft Guidance. Washington, DC: FDA; July 1999.Google Scholar
  18. 18.
    Grace D, Rogers J, Skeith K, Anderson K. Topical diclofenac versus placebo: a double blind, randomized clinical trial in patients with osteoarthritis of the knee.J Rheumatol. 1999;26: 2659–2663.PubMedGoogle Scholar

Copyright information

© Health Communications inc 2002

Authors and Affiliations

  • Otto Knuesel
    • 1
  • Michel Weber
    • 2
  • Andy Suter
    • 2
  1. 1.Department of RheumatologyValens Clinic for RheumatismValensSwitzerland
  2. 2.Bioforce AGRoggwilSwitzerland

Personalised recommendations